RET/PTC Inhibitors
2 drugsAbout RET/PTC
The rearranged during transfection/papillary thyroid carcinoma (RET/PTC) fusion protein results from chromosomal rearrangements, creating constitutively active kinases that drive cell proliferation and survival. The fusion involves the tyrosine kinase domain of the RET receptor and various N-terminal partners. It functions as an oncogenic driver.
RET/PTC is a therapeutic target in oncology, though no direct genetic evidence currently links it to specific diseases. Its role as an oncogenic driver makes it a valuable target for cancer therapies. Inhibiting RET/PTC activity can disrupt cancer cell growth.
Two approved drugs, including SORAFENIB TOSYLATE (NEXAVAR), target RET/PTC, both are small molecules. These drugs, developed by Viatris and Bayer, are approved for oncology and other therapeutic areas. Further development of selective inhibitors is possible.
Top RET/PTC Drugs
The competitive landscape includes Viatris and Bayer, the companies with approved drugs.
Limited competition suggests opportunity for new entrants with differentiated RET/PTC inhibitors.
RET/PTC Drug Modality Landscape
Modalities
Routes of Administration
RET/PTC is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation and novel IP.
RET/PTC Clinical Trials 383 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on RET/PTC. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 155 | 113 | 33 | 8 | 77% |
| Phase 2 | 168 | 100 | 46 | 21 | 68% |
| Phase 3 | 55 | 36 | 11 | 8 | 77% |
| Phase 4 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
RET/PTC Drug Approval Timeline (2005 - 2020)
The first drug was approved in 2005 (NEXAVAR), and the most recent in 2020 (SORAFENIB TOSYLATE).
The 16-year span between approvals indicates a potentially underserved market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 209 (56 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on RET/PTC. A trial counts if an approved drug acting on RET/PTC is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.